Navigation Links
Once-a-year Drug Reduces Fractures from Osteoporosis

A treatment for osteoporosis delivered once a year is as effective as current monthly or weekly osteoporosis regimens at reducing the incidence of bone fractures, according to a new study led by a UCSF research team.

Results from a three-year, international study of 7,736 postmenopausal women with osteoporosis are reported in the May 3, 2007 issue of the "New England Journal of Medicine." Study findings also are available online at content.nejm.org.

The study showed that treatment with zoledronic acid (marketed as Reclast) was very effective in reducing the incidence of all types of fractures in women with postmenopausal osteoporosis, the researchers said. Impact included a 70 percent reduction in the risk of spinal fractures and a 40 percent reduction in the risk of hip fractures. The effect was sustained over three years.

"The reductions in hip and spine fractures were at least as large as those seen with other drugs in this category," said Dennis Black, PhD, a professor of epidemiology and biostatistics in the UCSF School of Medicine, who led the study. "But even more remarkable were the strong, significant and consistent effects across all fracture types."

Reclast is an investigational drug in the bisphosphonate drug category that is being developed by Novartis Pharmaceuticals Corp., a U.S. affiliate of the Swiss-based Novartis AG. It is the only once-yearly bisphosphonate treatment being studied for osteoporosis and is still in the approval process through the Food and Drug Administration.

Three other drugs in the bisphosphonate family (marketed as Fosamax, Actonel and Boniva) are currently available and most commonly used as a once per week or once per month pill.

"For the first time, women could have the option of being treated once a year for osteoporosis, instead of having to remember to take a weekly pill," Black said. "Adherence to these weekly and monthly regimens is of ten a problem, so an annual treatment means patients are far more likely to actually receive valuable protection against potentially devastating fractures."

Postmenopausal osteoporosis affects millions of women worldwide, Black said, including more than 50 million women in the United States, Europe and Japan combined. Half of those women over age 50 will suffer from an osteoporotic fracture in their lifetime and, of women over age 65 who fracture a hip, 21 percent will die within one year as a result of poor underlying health status, in addition to the acute effects of the fracture.

The study, formally called Health Outcomes and Reduced Incidence with Zoledronic acid Pivotal Fracture Trial, known as HORIZON, was a multinational, randomized, placebo-controlled trial. It evaluated the potential of using a once-yearly infusion of 5 mg of zoledronic acid to decrease the risk of vertebral and hip fractures in postmenopausal women with osteoporosis.

The study also closely examined and put to rest several questions of other side effects of zoledronic acid, such as the renal damage and bone deterioration that has been seen at much larger doses in oncology treatments. The HORIZON study showed no such findings at the lower dose required for osteoporosis treatments.

The study did observe a small increase in the incidence of atrial fibrillation in patients who received zoledronic acid (1.3 percent for zoledronic acid versus 0.5 percent for placebo). Atrial fibrillation is a condition of abnormal heart rhythms, which is one risk factor for stroke.

"The observed increase in atrial fibrillation was very small less than one in 100 patients so it needs to be weighed against the reduction in fracture risk," Black said. This increase was unexpected and has not been seen in other studies of zoledronic acid. He recommends that it be further examined.

The May 3 issue of "NEJM" also includes a letter reg arding a separate study on a different drug in the bisphosphonate family, which showed a similar, but not statistically significant, increased risk of atrial fibrillation. That study also was conducted by the UCSF group.

As was expected, there was also a slight increase in minor side effects, such as fever or muscle pain. Those effects were seen within three days of the first infusion but not after the second or third.


'"/>




Related medicine news :

1. Drug Reduces Risk of Clogged Arteries, Veins
2. Sunshine Reduces MS Risk
3. Estrogen in Food Reduces Cancer Risk
4. Dental Procedure Reduces Preterm Births
5. Vaccine Reduces antibiotic-resistant infections in Children
6. Eating Fiber Reduces The Risk Of Heart Disease
7. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
8. Anti-tobacco Advertising Can Reduces smoking Among Teens
9. Eating Fish Reduces Heart Disease
10. Co-trimoxazole Use Reduces Childhood AIDS –Related Death
11. NSAIDS, Reduces The Risk Of Oral Cancer But Causes Heart Attacks
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
Breaking Medicine Technology: